Managers / Q4 2019 · view latest →
S. MUOIO & CO. LLC
CIK 0001138996 · 509 MADISON AVE, SUITE 406, NEW YORK, NY, 10022 · 212-297-2555
Summary
S. Muoio & Co. LLC reported $111M in U.S.-listed holdings across 71 positions for Q4 2019.
Its largest position, Allergan, represents 5.7% of the portfolio.
Compared with Q3 2019, the fund opened 17 new positions and exited 21.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 71.0% · $79M
- ETP · 15.0% · $17M
- Other · 9.7% · $11M
- REIT · 4.2% · $5M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SLVISHARES SILVER TRUST | NEW | +1.00M | 1.00M | +$17M | $17M |
| VIACOMCBS INC | NEW | +101.3K | 101.3K | +$4M | $4M |
| AUDENTES THERAPEUTICS INC | NEW | +57.0K | 57.0K | +$3M | $3M |
| WABCO HOLDINGS INC | NEW | +15.0K | 15.0K | +$2M | $2M |
| MEDICINES COMPANY | NEW | +20.0K | 20.0K | +$2M | $2M |
| ARQULE INC | NEW | +50.0K | 50.0K | +$998,000 | $998,000 |
| CONTINENTAL BUILDING PRODUCT | NEW | +25.0K | 25.0K | +$911,000 | $911,000 |
| ACHILLION PHARMACEUTICALS | NEW | +139.9K | 139.9K | +$844,000 | $844,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $76M | 62 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $70M | 68 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $85M | 85 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $252M | 90 | Feb 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $130M | 107 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $118M | 100 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $93M | 81 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $92M | 79 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $88M | 72 | Nov 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $82M | 64 | Aug 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $77M | 63 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $111M | 71 | Feb 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $95M | 75 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $123M | 77 | Aug 2, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $109M | 66 | May 9, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.